Cancer dual gene therapy with Ad-ΔB/TRAIL and Ad-ΔB/IL-12 was synergistically interacted in suppressing human HCC in vitro and in vivo with enhanced activation of anti-tumor immunity and apoptosis, and also enhanced inhibition of tumor angiogenesis and vasculature. The gene discussed is TNFSF10; the disease is hepatocellular carcinoma.